From the previous phase 1b study, we targeted CSF levels of 5nM54 or greater and predicted levels of 4.5 ng/mL (8nM), which was within the range of the fyn Ki (inhibition constant) for AZD0530 (5-10nM) and the efficacious levels in Alzheimer disease model mice (5.8-14nM).27 The gene discussed is FYN; the disease is early-onset autosomal dominant Alzheimer disease.